 Mesoblast Limited NASDAQ: MESO announced 36-month follow-up results from the 400-subject Phase 3 trial of its allogeneic cell therapy rexlemestrocel-L in patients with chronic low back pain CLBP associated with degenerative disc disease DDD. The data showed a durable reduction in back pain lasting at least three years from a single intra-discal injection of rexlemestrocel-Lhyaluronic acid HA carrier. 